Aqumen Biopharmaceuticals, N.A. Report issue

For profit Phase 3
Founded: Fukuoka Japan (2005)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2007
NCT00596583
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

dimenhydrinate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1